Clinical Update: News on Two Cancer Gene Editing...
Mar. 24, 2022
Relevant Interviews, Disease and Trial Updates and Stock-Markets News posted by CRISPR Medicine News.
Check also Companies to Follow in 2022 and CMN Markets for the latest stock and market trends.
Always stay updated with the free CMN Newsletter.
Iovance Biotherapeutics
Main focus: Tumor infiltrating lymphocyte (TIL) therapies for the treatment of cancer
Company stage: Clinical
Diseases (gene editing): Cancer
Genome editing tool: TALEN
Funding stage: Public (NASDAQ:IOVA)
Location: San Carlos, CA, USA
Website: https://www.iovance.com/
Pipeline: https://www.iovance.com/clinical/pipeline/
Gene-editing partnerships: Cellectis
Iovance Biotherapeutics is a clinical stage company focusing on the development of cellular therapies. The company develops tumour infiltrating lymphocyte (TIL)-based therapies to treat various types of solid tumours. The company's engagemen in the gene-editing space comes through its collaboration with Cellectis, from which it has licenced the TALEN technology to develop PD-1 inactivated TILs.
